Business Wire

ADVA

Share
Sify selects ADVA as technology partner to deliver managed Ethernet services

ADVA (FSE: ADV) today announced that it has been selected as the strategic technology partner of Sify Technologies Limited. Sify, the largest ICT service provider in India, is deploying the ADVA FSP 150 as the foundation of its new managed Ethernet service offering. The intelligent, multi-layer demarcation and aggregation technology will enable Sify to deliver secure, highly reliable end-to-end Ethernet services, leveraging its nationwide MPLS core network. The offering completes Sify’s ICT solution suite and empowers its end users to streamline operations, cut costs and rapidly seize new business opportunities. In addition to providing intelligent managed enterprise services, Sify will use the ADVA technology to extend its wholesale service footprint, giving more international carriers access to the Indian subcontinent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005040/en/

“Our new managed Ethernet offering fills the final gap in our portfolio. With ADVA as our technology partner, we can roll out high-capacity Layer 2 services with total flexibility and bring intelligence and automation to the edge of our enterprise network,” said Harsha Ram, VP, telecom services, Sify. ”The ADVA FSP 150 delivers new levels of agility for service innovation. It empowers us to provide the ideal solution for the budget, strategy and technical needs of each and every customer. What’s more, with ADVA’s technology, we can put IP traffic control at the end user’s fingertips. With incredible speed and efficiency, customers can take charge of their services, managing IP addresses and altering IP routing without restriction.”

With more than 10,000 enterprise customers across the Indian subcontinent, Sify has seen an enormous increase in data demand. The ADVA FSP 150 is the ultimate response. Deployed at the customer premises, the ADVA FSP 150 demarcation solution delivers MEF-certified CE 2.0 services and provides several key advantages. It’s highly interoperable, enabling seamless integration with Sify’s existing network management system. With its comprehensive set of service assurance functions, the solution offers full visibility of service quality – an essential tool for effective SLA management. The device also provides the flexibility to quickly transition from 1Gbit/s to 10Gbit/s Ethernet services without requiring extra space and power consumption.

“Our FSP 150 technology has always been at the forefront of Ethernet access innovation. Now we’re using all of our experience as a global leader with an enormous installed base to bring scalable, SLA-assured business and cloud access to Sify’s customers. With our multi-technology platform, Sify will be able to reduce costs and significantly simplify operations,” commented Sivakumar Krishna Iyer, director, global business development, ADVA. “Our FSP 150 provides comprehensive assurance, delivering unparalleled support for SLA management. It also effortlessly expands from 1GbE to 10GbE. What’s more, our solution offers zero-touch provisioning as standard so it can easily be installed and connected by customers with no risk of error. This makes it the ideal technology to enable major operators like Sify to rollout tomorrow’s business connectivity on an enormous scale.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com .

About Sify Techologies
Sify is the largest ICT service provider, system integrator and all-in-one network solutions company on the Indian subcontinent. We’ve also expanded to the United States, with headquarters in the heart of California’s Silicon Valley. Over 10,000 businesses have become Sify customers. We also partner with other major network operators to deliver global network solutions. Our customers can access Sify services via India’s largest MPLS network. Among the very few enterprise class players in India, Sify, today has presence in more than 1,600 cities in India and in North America, the United Kingdom and Singapore. www.sifytechnologies.com

Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye